Mantle cell lymphomas (MCL) are morphologically and immunophenotypically distinctive lymphoid neoplasms characterised by overexpression of cyclin D1. Recent studies have suggested that co-operating aberrations of cell cycle associated genes may provide a growth advantage to a tumour. To address this issue further, we investigated five typical and three aggressive (blastoid) MCL for alterations in the cell cycle regulating genes p15, p16, CDK4, Rb and p53. In 3/3 aggressive cases with cyclin D1 overexpression we found aberration of at least one additional gene. One case showed diminished expression of the retinoblastoma protein (pRb); one case harboured deletion of both p15 and p16; and one case exhibited both deletion of p16 and point mutation of p53. However, we also identified two typical cases which in addition to cyclin D1 overexpression exhibited diminished pRb expression and p15 and p16 hypermethylation, respectively. Our findings confirm and extend other recent investigations and indicate that co-operating genetic alterations of cell cycle-associated genes may contribute to the pathogenesis of MCL.
Introduction
Mantle cell lymphoma (MCL) is a relatively rare, but distinctive B cell non-Hodgkin's lymphoma (NHL). 1 The neoplastic cells contain irregular (cleaved) nuclei and show diffuse or, more rarely, nodular infiltrates with a mantle zone type of distribution pattern in involved lymph nodes. The cells are usually small-to medium-sized, but rare cases may be blastoid or anaplastic in appearance. 2 The clinical course in MCL is relatively aggressive with an overall median survival of 43 months and an even more aggressive behaviour in blastoid/anaplastic variants. 3 The phenotypic and genotypic properties of MCL have been studied in considerable detail. MCL cells show a characteristic immunophenotype (CD20
+ , CD23 − ) and overexpress cyclin D1 in the majority of cases. In normal lymphocytes cyclin D1 expression is not detected by immunohistochemistry. In most MCL, a specific chromosomal rearrangement, t(11;14)(q13;q32), induces overexpression of cyclin D1, as the cyclin D1 gene (BCL-1/CCND1/PRAD-1) on 11q13 is brought under transcriptional control of the immunoglobulin heavy chain enhancer elements on 14q32.
Cyclin D1 is an important stimulator of mammalian cell cycling. It promotes progression through G1 by interaction with cyclin-dependent kinases (CDK) 4 and 6. The cyclin D1-CDK4/6 complexes accelerate phosphorylation of the retinoblastoma protein (pRb), causing release of transcription factors which are essential for the expression of S-phase genes. This process is negatively regulated by specific and general CDK Correspondence: E Ralfkiaer, Department of Pathology, Herlev Hospital, 75 Herlev Ringvej, DK-2730 Herlev, Denmark; Fax: 45 4453 2604 Received 8 January 1998; accepted 6 April 1998 inhibitors (p15,p16,p21), and by p53 which exerts its effect by inducing transcription of p21. There are also indications that cyclin D1 can inactivate or reduce the expression of pRb by physical interactions which are independent of phosphorylation. 4, 5 Consistent with their roles in cell cycle control, all of the above-mentioned genes have been found to be altered in human malignancies, although at highly variable frequencies.
Recent evidence suggests that different genetic aberrations can co-operate to deregulate G1 control in human malignancies. 6, 7 These studies predict that tumours with alterations in more than one cell cycle-related gene are likely to have a higher proliferative activity and a more aggressive behaviour than 'one-hit' tumours. MCL are attractive neoplasms to study in this respect because of their consistent overexpression of cyclin D1. In this study, we have examined the status of cyclin D1, p15, p16, CDK4, p53 and pRb in eight MCL and compared these data with the histological features, proliferative rate and clinical course.
Materials and methods

Patients and tissue samples
Histological samples and clinical records of 157 NHL were reviewed retrospectively. The lymphoma specimens were classified in accordance with the REAL classification. 2 Eight patients had MCL of common (n = 5) or blastoid (n = 3) subtype, and these patients were included in the study. In all cases, both routinely processed histological samples and frozen tissue blocks were available. The frozen blocks had been frozen immediately after excision in either liquid N 2 or a mixture of 2-methyl butane and dry ice. The specimens were kept at −80°C until analysis.
Immunohistochemistry
Sections of frozen or routinely processed histological samples were examined by immunohistology for expression of CD20 (L26), CD79a (JCB117), CD3 (polyclonal rabbit anti-CD3), CD5 (4C7), CD23 (MHM6), bcl-2 (124), cyclin D1 (P2D11F11), p53 (DO7), Ki-67 (MIB1) and pRb (1F8, which recognises both phosphorylated and unphosphorylated pRb). In all cases, staining was performed with three-stage immunoperoxidase methods 8 using a commercially available substrate kit (DAKO-Superkit, Glostrup, Denmark). In the routine specimens, antigen retrieval by pre-treatment in a microwave oven was performed in the case of antibodies against CD3, CD5, bcl-2, cyclin D1, pRb and Ki-67 using either a citrate (pH 6) or a TEG (pH 8.6) buffer. The proportion of cells expressing p53, pRb, cyclin D1 and Ki-67 was estimated by assessment of the ratio of stained to unstained nuclei in representative areas at 40 times magnification. Reactions for p53, pRb and cyclin D1 were scored as negative if less than 10% of the nuclei were labelled.
DNA extraction and PCR
DNA from frozen tissue sections was extracted either by proteinase K digestion and phenol-chloroform extraction according to standard procedures or by means of the Puregene DNA Isolation Kit (Gentra, Minneapolis, MN, USA). Thermal cycling was carried out with the GeneAmp PCR System 9600 (Perkin-Elmer Cetus, CA, USA).
Translocation analysis
The t(11;14)(q13;q32) translocation in the major translocation cluster region (MTC) was detected by PCR using a consensus Ig JH primer for chromosome 14 and two different primers for the 11q13 region, as previously described. 9 The JVM-2 B cell leukemic cell line which carries the t(11;14) translocation was used as positive control. The t(14;18) translocation was detected by PCR as described in detail elsewhere, 10-12 using primers for the major breakpoint region 10 and minor cluster region 11 together with an Ig JH consensus primer. 12 The DOHH2 lymphoma cell line which carries the t(14;18) translocation was used as positive control.
Deletion analysis
Deletions of the p15 and p16 genes were detected by semiquantitative duplex PCR, essentially as described. 13 Oligonucleotide primers for p16 exons 1 and 2 and for the internal control sequence on chromosome 9q (STS) were as described. 13, 14 The primers for exon 1 of the p15 gene were 5′-AGCTGAGCCCAGGTCTCCTA-3′ and 5′-CGCCTCCCGAAACGGTTGAC-3′. PCR amplification was maintained within the exponential range (20-24 cycles) in 10 l volumes including [␣-33 P]dATP for labelling. The products were separated on a 2% agarose gel, which was subsequently dried and exposed to a Storage Phosphor Screen (Molecular Dynamics, Sunnyvale, CA, USA). A case was considered to be deleted when the ratio of target gene to reference gene was less than 0.2 of that observed in normal controls, and if the results were reproducible in at least three independent experiments. DNA from the DOHH2 lymphoma cell line which harbours homozygous deletion of the p16 gene, was used as positive control when mixed with DNA from peripheral blood lymphocytes of healthy individuals.
Methylation-specific PCR
Bisulphite treatment of DNA was performed essentially as described. 15 Approximately 1 g of genomic DNA was denatured in 0.3 m NaOH, followed by the addition of sodium bisulphite to a final concentration of 3.1 m and hydroquinone to a final concentration of 2.5 mm. After incubation at 55°C for 16 h, the DNA samples were recovered by using the GeneClean II kit (Bio 101, Vista, CA, USA), desulphonated in 0.3 m NaOH and ethanol-precipitated. PCR was performed in volumes of 25 l containing 1 × PCR buffer (10 mm Tris-HCl (pH 8.3), 50 mm KCl, 1.5 mm MgCl 2 , 0.01% (w/v) gelatin) 0.2 mm dNTPs, 0.8 m each primer, 0.2 mm cresol red, 12% sucrose, 100 ng of DNA, and 1 U of AmpliTaq polymerase (PerkinElmer Cetus). Four different sets of primers 16 which selectively amplify the p15 and p16 genes in their methylated (M) or ummethylated (UM) states were applied to each sample. Amplification was performed with the GeneAmp PCR system 9600 (Perkin-Elmer Cetus) as follows: 40 cycles of 94°C for 20 s, the appropriate annealing temperature for 20 s and 72°C for 30 s. The annealing temperature was 60°C for p16 M and UM, and 58°C and 55°C for p15 M and UM, respectively. Taq polymerase and dNTPs were added to the reaction tube at an 80°C step between the denaturation and annealing steps of the first cycle (hot start). The Burkitt lymphoma cell line Raji, which is completely methylated at the promotor CpG island of p16 and partially methylated at the p15 promoter, was used as positive control.
Denaturing gradient gel electrophoresis (DGGE), single-strand conformation polymorphism (SSCP), and direct sequencing
The entire coding sequence of the CDK4 and p53 genes was screened for mutations by PCR in combination with denaturing gradient gel electrophoresis (DGGE). 17, 18 Exons 1 and 2 of the p16 gene were amplified using the primers described by Hussussian et al 14 and screened for mutations by means of single-strand conformation polymorphism (SSCP). Direct sequence analysis of samples showing abnormal band patterns by DGGE or SSCP was performed using a 33 P-endlabelled primer and the ThermoPrime Cycle Sequencing Kit (Amersham, Cleveland, OH, USA).
Results
The histological, immunohistochemical and genotypic data are summarized in Table 1 . A selected case is illustrated in Figure 1 . Examination of routinely processed histological samples showed that five cases had a typical/common-type morphology with diffuse infiltrates consisting of small-to medium-sized cells with irregular (cleaved) nuclei while the remaining cases showed a blastoid appearance (n = 3). The neoplastic cells were positive for CD20 and CD79a and negative for CD3 in all cases. CD5 was positive in all but one blastoid case (No. 7). Expression of CD23 was examined in three cases. In these cases, CD23 stained scattered follicular dendritic cells, but did not label the neoplastic cells. Bcl-2 was positive in all cases, but none of them showed a t(14;18) translocation.
Cyclin D1
Immunohistochemical staining of paraffin sections was feasible in five cases. In all of these cyclin D1 was overexpressed by a majority of the neoplastic cells (Figure 1 ). PCR revealed a t(11;14)(13;q32) translocation in two of eight cases both of which were of blastoid histology.
p16, p15 and CDK4
Two of three aggressive cases had deletions of the p16 gene. Case No. 8 had a deletion of exon 2, and case No. 7 had a 
MTC, major translocation cluster region; CDK, cyclin-dependent kinase; ND, not done.
deletion involving exons 1 and 2 of p16 as well as the first exon in the adjacent p15 gene. No deletions were detected in cases with typical/common histology, but one of these cases (No. 4) showed inactivation of p15 and p16 by promoter hypermethylation (Figure 2) . None of the eight cases showed p16 or CDK4 point mutations.
Rb protein
The Rb antibody stained the nuclei in a majority of the neoplastic cells in six cases (Table 1 ). In the remaining two cases, only very occasional cells were stained and these cases were scored as pRb negative. One of the pRb-negative MCL had a blastoid morphology and a high proliferative rate (60% Ki-67-positive cells). The other patient showed a typical/commontype morphology and a lower proliferative rate (10% Ki-67-positive cells).
p53
In one of eight cases PCR/DGGE analysis of the p53 gene showed an aberrant band pattern (Figure 3 ). Direct sequence analysis revealed a G to A transition at the second base of codon 273, causing the replacement of arginine with histidine. The DGGE analysis revealed loss of the second allele, as indicated by an intense mutant homoduplex band as compared with a weak wild-type homoduplex band. The hemizygous p53 mutation was detected in a blastoid variant which also carried a p16 deletion and a t(11;14)(q13;q32) chromosomal translocation.
Examination for p53 protein expression was negative in five cases. In the remaining three patients, 10-50% of the neoplastic cells were p53 positive. The labelling was restricted to the nuclei and varied from weak to strong with the most intensive reaction being identified in the patient in whom a missense mutation had been detected by DGGE.
Proliferation (Ki-67)
The proliferative rates were 30, 50 and 60% in the blastoid cases. The proliferative rate in the typical/common-type cases was somewhat lower although variable from case to case (10, 10, 10, 20 and 50%).
Clinical data
The clinical follow-up data are summarized in Table 2 . The patients were four males and four females, aged 34-93 years (mean 67 years) at diagnosis. Four of the patients had associated -probably lymphoma-related -diseases. Two patients had autoimmune thyroid disease, one patient had autoimmune glomerulonephritis and one patient suffered from severe cryoglobulinemia of the fibrinogen type. All cases were at an advanced clinical stage with blood, bone marrow and/or spleen involvement in five cases. All blastoid cases progressed during chemotherapy in contrast to the typical cases in which at least partial remissions were obtained. Survival tended to be shorter in the blastoid group, and all of these patients died from progressive lymphoma 7, 24 and 32 months after diagnosis, respectively. The corresponding data for the typical cases were 65, 45, 36 and 18 months. One patient was lost to follow-up after 24 months.
Discussion
In this study, we demonstrate that MCL can show abnormalities of several genes involved in the normal control of transition from G1 to S of the cell cycle. Three of three blastoid cases showed, in addition to cyclin D1 overexpression, aberration of at least one of the tumour suppressor genes p16, p15, Rb and p53. One case showed diminished pRb expression; one case carried deletion of both p15 and p16; and one case exhibited both deletion of p16 and point mutation of p53. Aberrations of these genes were not restricted to blastoid cases, but were also seen in typical cases, two of which showed cyclin D1 overexpression in addition to p15 and p16 hypermethylation (one patient) and diminished pRb expression (one patient).
It is well established that overexpression of cyclin D1 is a key feature in MCL, and more than 70% of cyclin D1-positive cases can be shown to harbour the t(11;14) chromosomal translocation when analysed with multiple break-point Immunohistochemical staining of paraffin sections of a mantle cell lymphoma (No. 8). The neoplastic cells are positive for CD79 and CD5, and negative for CD3 and CD23. Cyclin D1 and pRb are expressed by a majority of the neoplastic cells. Ki-67 is positive in 50% and p53 in 10% of the cells.
probes. 19 In our study, cyclin D1 could be detected in 5/5 evaluable cases by means of immunohistochemistry. The t(11;14) chromosomal rearrangement was detected by a PCRbased method which only detects breaks in the major translocation cluster region. By means of this method we detected t(11;14) in 2/8 cases, both of which were blastoid and carried a p16 deletion.
In this study, we found high levels of pRb in all cases, except for one blastoid case and one typical case which both showed low to undetectable levels of pRb by immunostaining. Computerised quantitative studies have indicated that pRb is expressed at low levels in tumours with low proliferative rate. 20, 21 This observation may explain our finding of low pRb expression in a typical case with low proliferative rate. Because cyclin D1 should confer no growth advantage to a pRb-negative tumour, 6 cyclin D1 overexpression may have preceded loss of pRb. Only few previous cases of pRbdepleted MCL with high proliferation rates and aggressive his-
Figure 2
Methylation status of the p15 promoter region in mantle cell lymphomas analysed by methylation specific PCR. DNA was bisulphite-reated and amplified by PCR using primers specific for unmmethylated (U) or methylated (M) DNA. DNA from peripheral blood lymphocytes (PBL) was used as positive control for unmethylated DNA, and the Burkitt cell line RAJI as positive control for methylated DNA. Case No. 4 shows a band specific for methylated DNA, while the remaining MCL are unmethylated (*, 100-bp ladder). tology have been reported 20, 22, 23 In a recent study Dreyling et al 24 identified hemizygous deletions at the Rb locus in MCL by fluorescence in situ hybridisation (FISH). However, they found no correlation with the proliferative rate and could not exclude the possibility that another nearby gene might have been the target of the observed genomic lesions. Given these observations it seems implausible that deletion of Rb is the cause of low pRb level in our series, and it remains unclear whether the proliferative activity of MCL depends upon the phosphorylation status of pRb rather than upon the actual amount of protein present.
The possibility that co-operative genetic alterations of the p16-CDK4/6-cyclin D1-pRb pathway may provide a growth advantage to neoplastic cells was initially suggested on the basis of studies in cell lines. Deletion, mutation or hypermethylation of p16 was demonstrated in up to 66% of tumour cell lines with aberrations of the cyclin D1 gene. 6 More recently, the possibility that the 'two hit' hypothesis may also be significant under in vivo conditions has been supported by the observation that some primary MCL show alterations in both cyclin D1 and p16. Pinyol et al 9 found deletion of p16 in three of six aggressive (blastoid/anaplastic) MCL, but in none of 18 typical cases. Dreyling et al 24 identified deletions of p16 in 15/37 MCL by FISH. They demonstrated a tendency towards a higher frequency of p16 deletions in blastoid variants and a significant correlation between p16 deletions and the proliferative rate. This is in keeping with the present study in which p16 deletions were identified in two of three blastoid cases, both of which had relatively high proliferative rates and showed an aggressive behaviour. Both cases had high levels of pRb, indicating that p16 and cyclin D1 may co-operate to overcome the inhibitory effect of pRb.
Promoter hypermethylation causes loss of gene expression 25 and has been identified as an important mechanism of inactivation of tumour suppressor genes in a variety of hematopoietic malignancies. 26 The literature reports hypermethylation of p16 in 2/5 'low-grade' MCL. 27 In our series, hypermethylation of p16 as well as p15 was detected in one cyclin D1-positive case with a typical/common morphology. Concomitant alterations of these genes did not seem to render this lymphoma particularly aggressive. Clinically, this 93-year-old patient responded well to standard-dose chlorambucil and attained a partial remission. However, after 18 months she died due to pneumonia in cytopenia.
In this study we did not identify any point mutations of p16 which is consistent with previous observations which have shown that the overall frequency of mutation of p16 in lymphoma is low. Taken together these findings indicate that deletions and hypermethylation are the main mechanisms of p16 inactivation in MCL.
Alterations of the p53 gene in addition to cyclin D1 overexpression is the most consistently observed genetic aberration in aggressive MCL. The reported frequency of p53 point mutations in aggressive variants ranges from 28 to 50%. This is in keeping with our finding of one mutant case among three blastoid cases. The R273H mutation is known to cause loss of normal p53 function, 28 and the observation that the second allele is deleted corroborates that this tumour is completely devoid of functional p53. The p53 mutation was identified in a case of MCL which also showed deletion of p16 and overexpression of cyclin D1.
Concomitant alterations of p16 and p53 have been detected in cell lines and primary tumours, including lymphoma, but to our knowledge this is the first report of concomitant aberrations of p53 and p16 in a t(11;14)(q13;q32)-positive tumour. The patient survived for 32 months, suggesting that a 'threehit' tumour is no more aggressive than a 'two-hit' tumour. However, the relatively 'indolent' behaviour in this particular case may be related to the relatively young age of the patient which allowed for heavy treatment with various aggressive chemotherapeutic regimens.
In conclusion, the present report confirms and extends previous studies, and indicates that co-operating oncogenic events associated with deregulation of G1 control may contribute to the pathogenesis of MCL. Whether tumours harbouring multiple hits arise de novo or evolve from typical MCL through a multi-step process remains unknown. The relative contribution of the individual hits to tumorigenesis and their means of co-operation are poorly understood, and this topic will be an important issue for future investigations.
